source
- Oxford biotech OMass Therapeutics secures $310 million to advance genetic adrenal disorder programOxford-based OMass Therapeutics announced a $310 million private financing round, one of the largest recent fundraises for a UK biotech. The capital will fund the development of therapies targetin…
- Iambic Therapeutics raises $150 million in IPO, begins Nasdaq trading under ticker IAMIambic Therapeutics, an AI-driven drug discovery startup, completed an initial public offering that raised $150 million. The company sold about 9.4 million shares at $16 each and will start tradin…